Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 3/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.40 |
| ▸ | BRAF | P15056 | 3/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3125372 | 0.94 | SIRT2 (0.47) | BACE1MCL1RAF1SIRT2BRAF | |
| SCHEMBL3112843 | 0.89 | AGPAT2 (0.45) | P2RX3AGPAT2RAF1BRAFSCN9A | |
| SCHEMBL3119465 | 0.89 | AGPAT2 (0.53) | P2RX3AGPAT2RAF1BRAFSCN9A | |
| SCHEMBL3125885 | 0.88 | P2RX3 (0.46) | P2RX3AGPAT2RAF1BRAFSCN9A | |
| SCHEMBL3119717 | 0.87 | P2RX3 (0.46) | P2RX3AGPAT2RAF1BRAF | |
| SCHEMBL3125322 | 0.86 | RAF1 (0.45) | P2RX3AGPAT2BTKRAF1BRAF | |
| SCHEMBL3115031 | 0.85 | ABL1 (0.51) | RAF1BRAFSCN9A | |
| SCHEMBL3125410 | 0.85 | P2RX3 (0.46) | P2RX3AGPAT2RAF1BRAFSCN9A | |
| SCHEMBL3108918 | 0.85 | KDR (0.47) | P2RX3AGPAT2RAF1BRAF | |
| SCHEMBL1644941 | 0.84 | RAF1 (0.47) | AGPAT2RAF1SIRT2BRAFSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-7678804-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678804-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678804-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-03-16 | — | — | US | disclosed |
| US-7582645-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582645-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582645-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | US | disclosed |
| US-20050277640-A1 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | TYMP, DPYD, CCNA2 | BACE1 4684/4885P2RX3 1430/4885MCL1 275/4885 |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | CCNA2, MALT1, TPD52L2 | BACE1 4876/4885P2RX3 1510/4885MCL1 27/4885 |
| US-20050277640-A1 | Pyrimidine derivatives for treatment of hyperproliferative disorders | TYMP, DPYD, CCNA2 | BACE1 4684/4885P2RX3 1430/4885MCL1 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.